Aivita Biomedical, an Irvine, CA-based biotech company specializing in innovative stem cell applications, received $1.7m in funding.
The California Institute for Regenerative Medicine (CIRM) has provided the award.
The company intends to use the funds for further development of their stem cell-derived three-dimensional retina to treat vision loss.
Founded in 2016, Aivita Biomedical is engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. The company’s ROOT OF SIGHT technology uses three-dimensional retina sheets created from human stem cells, transplanted into the back of the eye, to replace lost retina and improve visual acuity. Aivita’s Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable manufacturing systems which support its commercial line of skin care products and therapeutic pipeline.
All proceeds from the sale of its ROOT OF SKINTM skin care products support the treatment of women with ovarian cancer.